Navigation Links
NanoViricides Drugs Found To Be Highly Effective Against Most,Recent Strain of the H5N1 Avian Flu Virus

WEST HAVEN, Conn.--(BUSINESS WIRE)--May 7, 2007 - NanoViricides, Inc. (Pink Sheets: NNVC) presented results of recent animal studies against rabies and BSL3 in vitro studies against a Clade 2 H5N1 (avian influenza) virus at the 23rd Annual Symposium of the Pan American Society for Clinical Virology in Tampa, FL, on Wednesday, May 2. (Pan American Society for Clinical Virology (PASCV): Clinical Virology Symposium)

The BSL3 studies against Clade 2 H5N1, a Dec. 2006 isolate in Vietnam, showed that the nanoviricide developed against Highly Pathogenic Influenzas, FluCide-HP (TM), was highly effective in suppressing cytopathic effects (CPE), whereas the broad-spectrum nanoviricide against all influenzas, FluCide(TM), was slightly less effective than AviFluCide-HP. These findings were expected. Both of these candidates were significantly more effective than oseltamivir (Tamiflu(R)) in this blind study performed by the National Institute of Hygiene and Epidemiology (NIHE) scientists in Vietnam.

In addition, the antibody-fragment-based H5N1 specific (Clade 1, Vietnam, 2004-2005 strains) AviFluCide(TM) drug candidate was demonstrated conclusively by Vietnam scientists to significantly suppress CPE against this rgH5N1 strain (Clade 1), confirming previous results.

The Highly Pathogenic H5N1 subtype of influenza continues to rapidly evolve and is now found in two distinct subgroups, Clade 1 and Clade 2. According to CDC scientists, the Vietnam 2004/2005 strains belong to Clade 1, whereas the Indonesia 2006 (2007), Egypt 2006, and Vietnam 2006 (2007) strains are different and form the Clade 2 subgroup. The various Clade 2 strains are antigenically distinct from each other, but closer to each other than to Clade 1 strains.

"Highly Pathogenic Influenza strains of all clades possess the polybasic cleavage site. Thus FluCide-HP, designed against this site, is expected to be effective against all Highly Path ogenic influenza strains. It makes no difference to which type, subtype, or clade, they belong," said Anil R. Diwan, Ph.D., president of NanoViricides, Inc.

"We have shown that our drug candidates are the most effective drugs at present against even the newest subgroup of H5N1 viruses. Other companies continue to work on developing vaccines and drugs against the older Clade 1 H5N1 viruses, while we are working on the newest strains," said Eugene Seymour, MD, MPH, Chief Executive Officer of NanoViricides, Inc.

The Company plans to comment shortly on its in vitro/in vivo rabies studies.

About NanoViricides: http://www.nanoviricides.com

NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for viral therapy. Nanoviricides is currently developing drugs against Common influenza, Bird Flu H5N1, Rabies, Dengue and other viruses with various collaborators. The Company recently signed a Cooperative Research and Development Agreement with the Walter Reed Army Institute of Research (http://wrair-www.army.mil/) for creating new treatments for dengue fever using NanoViricides' virus-killing nanomedicine technology. This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially and substantially from those projected herein and depend on a number of factors including the success of the Company's research and development strategy, the availability of adequate financing, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process.

Contact

NanoViricides, Inc.
Leo Ehrlich, 917-853-6440
leo@nanoviricides.com


'"/>




Related medicine technology :

1. Global Rabies Treatment May be Possible with NanoViricides Drugs
2. Monitoring Options Expand for Therapeutic Agents and Drugs of Abuse
3. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
4. New Drugs in Multinational Study Show Promise in Fighting Drug-Resistant HIV
5. New Report Looking at Chiral Technologies Analyzes the Global Market Growth Forecasts Driven By Two Very Important Components as Single Isomer Drugs and Single Enantiomer Pharmaceuticals
6. Array BioPharma Reports New Clinical Data on Its Anti-Inflammatory Drugs
7. Three New Drugs Mark New Era in Rheumatoid Arthritis Treatment
8. Major Manufacturer of Unapproved and Adulterated Drugs
9. Research Supported by Samuel Waxman Cancer Research Foundation Discovers Mode of Action of Arsenic-Based Drugs in Destroying Cancer Cells
10. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
11. Lupus Foundation of America Statement on Results for Clinical Study of CellCept Released by Aspreva Pharmaceutical Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... OAKLAND, N.J. , June 24, 2016 /PRNewswire/ ... in the design, development and manufacturing of collagen ... and regeneration announced today that Bill Messer ... Sales and Marketing to further leverage the growing ... surgery medical devices. Bill joins the ...
(Date:6/24/2016)... Va. , June 24, 2016 The ... set of recommendations that would allow biopharmaceutical ... (HCEI) with entities that make formulary and coverage decisions, ... the "value" of new medicines. The recommendations ... does not appear on the drug label, a prohibition ...
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ., ... developing innovative inhaled drugs, announced today that it was ... Investments reconstituted its comprehensive set of U.S. and ... "This is an important milestone for Pulmatrix," said Chief ... shareholder awareness of our progress in developing drugs for ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now ... of Final Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. ... Final Cut Pro X users can now reveal the media of their split ...
(Date:6/27/2016)... , ... June 27, 2016 ... ... the patient payment industry today announced its strategic partnership with Connance, a ... workflows. , The two companies’ proven, proprietary technology combine to provide health ...
(Date:6/27/2016)... Park, KS (PRWEB) , ... June 27, 2016 , ... ... in retailers of Eyeglasses . , Millions of individuals in the United States ... eyeglasses have become a way to both correct vision and make a fashion statement. ...
(Date:6/26/2016)... ... 2016 , ... On June 10-11, 2016, A Forever Recovery, a holistic treatment ... Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is located. This ... of the world’s leading providers of cereal and other breakfast foods. Its residents often ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... was developed to enhance the health of felines. The formula is all-natural and is ... herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus ...
Breaking Medicine News(10 mins):